The major limitation to targeted therapy of BRAF mutant tumors is the omnipresence of adaptive mechanisms at the genomic level, but also in re-programming of the tumor microenvironment17, which could also be reflected by the increased PD-L1 expression at the last progression. This evidence concerns the gene CD274 and neoplasm.